<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        196-325-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RIACAVILOL 25MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARVEDILOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        42.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AG02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Riacavilol belongs to a group of medicines called beta-blockers that work by relaxing and widening the blood vessels. This makes it easier for your heart to pump blood around the body and reduces blood pressure and strain on your heart.</p><p><strong>Riacavilol is used: </strong></p><ul><li>For the treatment of high blood pressure (hypertension),</li><li>For the treatment of chest pain that occurs when the arteries that supply your heart with blood carrying oxygen are narrowed which results in less oxygen reaching your heart muscles (angina),</li><li>For the treatment of weakening of the heart muscle (heart failure), in combination with other medicines.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Riacavilol</strong></p><ul><li>if you are&nbsp;<strong>allergic</strong>&nbsp;(hypersensitive) to Riacavilol or any of the other ingredients of Riacavilol (as listed in section 6 &#39;Further Information&#39;),</li><li>if you have a history of wheezing due to asthma or other lung diseases,</li><li>if you have been told you have very severe heart failure and you have fluid retention (swelling) which is being treated with injections of medicines into your veins (intravenously),</li><li>if you have liver disease,</li><li>if you have been told that you have a very slow heartbeat,</li><li>if you have very low blood pressure,</li><li>if you have been told you have a condition called Prinzmetal&#39;s angina,</li><li>if you have phaeochromocytoma (a tumor of the adrenal gland causing high blood pressure) which is not being treated,</li><li>if you are suffering from serious disturbances in the body&#39;s acid-base balance (metabolic acidosis),</li><li>if you have very poor blood circulation in the hands and feet resulting in coldness and pain in them,if you have a particular conduction defect of the heart (called an AV heart block Grade II or III (unless a pacemaker is fitted) or a SA block),</li><li>if you are currently being treated with injections of verapamil or diltiazem (used in the treatment of high blood pressure or heart problems),<p>If any of these apply to you, do not take Riacavilol.</p></li></ul><p><strong>Warnings and precautions</strong></p><p>It is important to&nbsp;<strong>tell your doctor before</strong>&nbsp;taking Riacavilol if you:</p><ul><li>Have been told you suffer from any other heart problems,</li><li>Have or have ever had any problems with your liver, kidneys or thyroid,</li><li>Have diabetes. Riacavilol may hide your usual symptoms of low blood sugar,</li><li>Have a skin condition known as psoriasis,</li><li>Have poor circulation affecting hands, feet or lower legs, or Raynaud&#39;s phenomenon,</li><li>Have or have ever had a serious allergic reaction or you are undergoing allergic desensitization therapy for any type of severe allergy,</li><li>Wear contact lenses because Riacavilol may cause the eyes to be drier than normal.</li></ul><p><strong>Other medicines and Riacavilol</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taking, have recently taken or might take any other medicines.</p><p><strong>The administration of Riacavilol</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or herbal medicines. Take particular care and tell your doctor or pharmacist, if you are taking any of the following medicines:</p><ul><li>medicines used to treat an irregular heartbeat (e.g. diltiazem, verapamil or amiodarone),</li><li>nitrate medicines for angina (e.g. isosorbide mononitrate or glyceryl trinitrate),</li><li>medicines used to treat heart failure (e.g. Digoxin),</li><li>any other medicine used to treat high blood pressure (e.g. doxazosin, reserpine, amlodipine or indoramin),</li><li>medicines used to treat depression or other mental health conditions (e.g. fluoxetine, tricyclic antidepressants, barbiturates, phenothiazines, haloperidol or monoamine oxide inhibitors (MAOls),</li><li>medicines used to prevent your body rejecting organs after transplant operations (e.g. cyclosporine),</li><li>medicines to reduce blood sugar such as oral antidiabetic medicines or insulin,</li><li>medicines used to reduce blood pressure or to treat migraine (e.g. clonidine or ergotamine),</li><li>certain painkilling agents such as non-steroidal anti-inflammatory medicines (NSAIDs) (e.g. ibuprofen or diclofenac),&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li><li>medicines used for hormone replacement therapy (e.g. estrogens),</li><li>corticosteroids used to suppress inflammatory or allergic reactions (e.g. prednisolone),</li><li>medicines used to treat bacterial infections (e.g. rifampicin or erythromycin),</li><li>medicines used to treat stomach ulcers, heartburn and acid reflux (e.g. cimetidine),</li><li>medicines used to treat fungal infections (e.g. ketoconazole),</li><li>medicines sometimes used in decongestant cough and cold remedies (e.g. ephedrine or pseudoephedrine),</li></ul><p>If you need to have an anaesthetic for an operation, tell your hospital doctor you are taking Riacavilol.</p><p><strong>Taking Riacavilol with food and drink</strong></p><p>You should take Riacavilol with water.</p><p>If you are taking Riacavilol to treat heart failure, you should take this medicine with water at your mealtime (see section 3 &#39;How to take Riacavilol)</p><p>Do not drink alcohol whilst taking Riacavilol as it might worsen the effects of alcohol.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding,&nbsp;<strong>do not take</strong>&nbsp;this medicine until you have talked to your doctor. Consult your doctor immediately if you become pregnant while taking this medicine.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>&nbsp;Driving and using machines</strong></p><p>You may experience dizziness or tiredness whilst taking Riacavilol. This is more likely to occur when you first begin treatment, or when the dose is increased. If this occurs, you should not drive or operate machinery. You should avoid drinking alcohol, as it may make these symptoms worse. If you are concerned or want more information, you should talk to your doctor.</p><p><strong>Important information about some ingredients of Riacavilol</strong></p><p>Riacavilol contains lactose (type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Riacavilol exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Riacavilol should be swallowed with a drink of water.</p><p><strong>High blood pressure</strong></p><p><em>Adults:</em>&nbsp;The usual starting dose is 12.5 mg once a day for the first two days.</p><p>After this, the dose is increased to 25 mg once a day. If necessary, your doctor may gradually increase the dose further at intervals of two weeks or more. The maximum recommended daily dose is 50 mg (the maximum recommended single dose is 25 mg).</p><p><em>Elderly:</em>&nbsp;Your doctor will usually start you on 12.5 mg once a day and continue with this dose for the length of your treatment. If necessary, your doctor may increase your dose gradually at intervals of two weeks or more.</p><p><strong>Angina</strong></p><p><em>Adults:</em>&nbsp;The usual starting dose is 12.5 mg twice a day for the first two days.</p><p>After this, the dose is increased to 25 mg twice a day. If necessary, your doctor may gradually increase the dose further at intervals of two weeks or more to a maximum of 100 mg a day in two doses.</p><p><em>Elderly:</em>&nbsp;The recommended starting dose is 12.5 mg twice a day for two days.</p><p>After this, the dose may be increased to 25 mg twice a day, which is the recommended maximum daily dose.</p><p><strong>Heart failure</strong></p><p><em>Adults and elderly:</em>&nbsp;For the treatment of stable heart failure, the tablets should be taken twice a day, in the morning and in the evening, and should be taken with food in order to reduce the risk of side effects.</p><p>The starting dose is 3.125 mg twice a day for two weeks. Your doctor will then gradually increase the strength of tablets you take at intervals of two weeks or more until you receive the dose that suits you best.</p><p>If you weigh less than 85 kg, the maximum recommended dose of Riacavilol is 25 mg twice a day, if you weigh more than 85 kg, your doctor may increase your dose to 50 mg twice a day.</p><p>For the treatment of heart failure, it is recommended that your treatment with Riacavilol is started and carefully monitored by a hospital specialist.</p><p>If you have stopped taking Riacavilol for more than two weeks, you will need to return to the starting dose and increase the dose gradually again.</p><p>Sometimes, your heart failure may worsen while taking Riacavilol, particularly at the start of your treatment. This may result in increased symptoms (e.g. tiredness, shortness of breath) and signs of fluid retention (e.g. weight gain and swelling of the legs).</p><p>If your symptoms or condition worsens whilst taking Riacavilol, you should tell your doctor, as he or she may need to change the dose of your other medications or of Riacavilol.</p><p>While taking Riacavilol, make sure that you continue with your other treatments for heart failure as advised by your doctor.</p><p><strong>Patients with liver problems</strong></p><p>Depending on your condition, your doctor may reduce your dose compared to those recommended above.</p><p><strong>Children and adolescents (under 18 years old)</strong></p><p>Riacavilol is not recommended in this age group.</p><p><strong>If you take more Riacavilol than you should</strong></p><p>If you accidentally take too many tablets, contact your doctor immediately or go to the nearest hospital casualty department. You may feel dizzy, sick, faint, breathless/wheezy, very drowsy, or experience convulsions.</p><p><strong>If you forget to take Riacavilol</strong></p><p>If you forget to take a dose, do not worry. Take another as soon as you remember, provided it is not nearly time for your next dose. Take your next tablet at the normal time, but do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Riacavilol</strong></p><p>Do not suddenly stop taking Riacavilol before you have spoken to your doctor about it. You may have side effects if you suddenly stop the tablets. Your doctor will tell you how to reduce the dosage gradually and then stop this medicine. If you are also taking a medicine called clonidine, never stop either treatment unless told to by your doctor.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The frequency of possible side effects is shown in the table below:</p><p><strong>Very common:</strong>&nbsp;occur in more than 1 in 10 users</p><p><strong>Common:</strong>&nbsp;occur in less than 1 in 10, but more than 1 in 100 users</p><p><strong>Uncommon:</strong>&nbsp;occur in less than 1 in 100 users but more than 1 in 1.000 users</p><p><strong>Rare:</strong>&nbsp;occur in less than 1 in 1.000, but more than 1 in 10.000 users</p><p><strong>Very rare:</strong>&nbsp;occur in less than 1 in 10.000 users, including isolated cases</p><p>The majority of side effects are dose-related and disappear when the dose is reduced or the treatment discontinued. Some side effects can occur at the beginning of treatment and resolve spontaneously as the treatment continues.</p><p><strong>Very common:</strong></p><ul><li>Dizziness</li><li>Headache</li><li>Tiredness</li><li>Low blood pressure</li><li>Heart failure</li></ul><p><strong>Common:</strong></p><ul><li>Bronchitis, pneumonia, upper respiratory tract infection</li><li>Infections of the urinary tract</li><li>Low numbers of red blood cells</li><li>Increase in weight</li><li>Elevated cholesterol levels</li><li>Loss of control of blood sugar in people with diabetes</li><li>Depression, depressed mood</li><li>Visual disturbance</li><li>Reduced lacrimation, eye irritation</li><li>Slow heart rate</li><li>Oedema (swelling of the body or parts of the body), fluid overload, increased volume of blood in the body</li><li>Dizziness when standing up quickly</li><li>Problems with blood circulation (signs include cold hands and feet), hardening of the arteries (atherosclerosis) worsening of symptoms in patients with Raynaud&#39;s disease (fingers or toes turn first bluish, then whitish, and then reddish together with pain) or claudication (pain in the legs which worsens when walking)</li><li>Asthma and breathing problems</li><li>Fluid accumulation in the lungs</li><li>Diarrhea</li><li>Malaise, vomiting, stomach pains, indigestion</li><li>Pains (e.g. in the arms and legs)</li><li>Acute renal insufficiency and disturbances in renal function in patients with hardening of the arteries and/or impaired renal function</li><li>Difficulty in passing urine</li><li>Elevated level of Potassium in blood.</li></ul><p><strong>Uncommon:</strong></p><ul><li><p>Sleep disturbance</p></li><li><p>Confusion</p></li><li><p>Fainting</p></li><li><p>Abnormal sensation</p></li><li><p>Disturbances in the heart&#39;s conduction system, angina pectoris (including chest pain)&nbsp;</p></li><li><p>Certain skin reactions (e.g. allergic dermatitis, hives, itching and skin inflammation, increased sweating, psoriatic or lichen planus like skin lesions)</p></li><li><p>Hair loss</p></li><li><p>Impotence</p></li></ul><p><strong>Rare:</strong></p><ul><li><p>Lowered blood platelet count (thrombocytopenia)&nbsp;</p></li><li><p>Mouth dryness (dryness of the mouth)</p></li><li><p>Stuffy nose</p></li></ul><p><strong>Very rare:</strong></p><ul><li><p>Low numbers of white blood cells</p></li><li><p>Allergic reactions</p></li><li><p>Changes in the liver function test</p></li><li><p>Involuntary leakage of urine in women (urinary incontinence).</p></li></ul><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach &amp; sight of children.</p><p>- Store below 30&deg;C.</p><p>- Store in the original package in order to protect from light and moisture.</p><p>- Do not use RIACAVILOL after the expiry date, which is stated on the blister or the package.</p><p>- Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each film-coated tablet contains Carvedilol (BP) 25 mg.</p><p>Other ingredients: Lactose (DC GRADE), Microcrystalline Cellulose PH1 02, Crospovidone, Colloidal Anhydrous Silica, Magnesium Stearate.</p><p>GOATING MATERIAL: Opadry Yellow 31.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                RIACAVILOL 25 mg: Yellow coloured film coated circular tablets having MC 12 on one side and break line on the other side.
Pack:
-	Each pack of RIACAVILOL 25 mg contains 30 film coated tablets: 3 (Alu/Alu) blisters, each blister contains 10 film coated tablets.
-	Hospital packs of RIACAVILOL 25 mg.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</strong></p><p>P.O. Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>&nbsp;For any information about this medicinal product, please contact the local representative of marketing authorization holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>رياكافيلول ينتمي إلى مجموعة من الأدوية تسمى حاصرات بيتا التي تعمل عن طريق الاسترخاء وتوسيع الأوعية الدموية. وهذا يجعل من الاسهل لقلبك على ضخ الدم في جميع أنحاء الجسم، ويقلل من ضغط الدم والضغط على قلبك</p><p>يستخدم رياكافيلول :</p><ul><li>لعلاج ارتفاع ضغط الدم (ضغط الدم)</li><li>لعلاج آلام الصدر التي تحدث عندما تضيق الشرايين التي تغذي القلب والتي تحمل الأكسجين في الدم مما يؤدي إلى قلة الأكسجين الذي يصل إلى عضلات القلب (الذبحة الصدرية)</li><li>لعلاج ضعف عضلة القلب (قصور القلب)، بالاقتران مع أدوية أخرى</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ رياكافيلول</p><ul><li dir="rtl">&nbsp; &nbsp; إذا كنت تعاني من حساسية (فرط الحساسية) لرياكافيلول أو أي من المكونات الأخرى من رياكافيلول (كما هو موضح في القسم 6 &quot;مزيد من المعلومات)</li><li dir="rtl">إذا كان لديك تاريخ من الصفير بسبب الربو أو أمراض الرئة الأخرى،</li><li dir="rtl">إذا كان قد قيل لك أن لديك فشل القلب الحاد جدا وكان لديك احتباس السوائل (تورم) الذي يعالج بحقن الأدوية في عروقك (عن طريق الوريد)</li><li dir="rtl">إذا كان لديك مرض الكبد،</li><li dir="rtl">إذا كان قد قيل لك أن لديك ضربات القلب بطيئة جدا،</li><li dir="rtl">إذا كان لديك انخفاض شديد في ضغط الدم،</li><li dir="rtl">إذا كان قد قيل لك أن لديك حالة تسمى الذبحة الصدرية من نوع برنزميتال،</li><li dir="rtl">إذا كان لديك ورم القواتم (ورم الغدة الكظرية يسبب ارتفاع ضغط الدم) والتي لا يتم علاجها،</li><li dir="rtl">إذا كنت تعاني من اضطرابات خطيرة في التوازن الحمضي القاعدي في الجسم (الحماض الأيضي).</li><li dir="rtl">إذا كان لديك عيب توصيل معين في القلب (وتسمى منع توصيل (ايه في) بالقلب من الدرجة 1أو 2(ما لم يتم تركيبها جهاز تنظيم ضربات القلب) أو منع توصيل،اس ايه.</li><li dir="rtl">إذا كانت الدورة الدموية سيئة للغاية في اليدين والقدمين مما يؤدي إلى برودة وألم فيهم،</li><li dir="rtl">إذا كنت حاليا خاضعا للعلاج بواسطة حقن فيراباميل أو ديلتيازيم (المستخدمة في علاج ارتفاع ضغط الدم أو مشاكل في القلب،</li></ul><p>إذا كان أي من هذه تنطبق عليك، لا تأخذ رياكافيلول.</p><p><strong>التحذيرات والاحتياطات</strong></p><p>من المهم أن تخبر طبيبك قبل اتخاذ رياكافيلول إذا:</p><ul><li>قيل لك أنك تعاني من أي مشاكل أخرى بالقلب،</li><li>كان لديك أو في أي وقت مضى أي مشاكل مع الكبد والكلى أو الغدة الدرقية،</li><li>كنت مصابا بداء السكري. رياكافيلول قد يخفي لديك الأعراض المعتادة لانخفاض نسبة السكر في الدم،</li><li>كان لديك حالة بالجلد المعروفة باسم الصدفية،</li><li>كان لديك ضعف بالدورة الدموية يؤثر على اليدين والقدمين أو أسفل الساقين، أو ظاهرة رينود،</li><li>كان لديك أو في أي وقت مضى حساسيه رد فعل خطير أو كنت تتلقى علاج مزيل الحساسية لأي نوع من الحساسية الشديدة،</li><li>ترتدي العدسات اللاصقة فقد يتسبب رياكافيلول لأن تكون العينين أكثر جفافا من المعتاد.</li></ul><p><strong>الأدوية أخرى ورياكافيلول </strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت في الآونة الأخيرة، أو قد تتناول أي أدوية أخرى.</p><p><strong>تناول رياكافيلول:</strong></p><p>يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية أو الأدوية العشبية. توخى الدقة بوجه خاص وأخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><ul><li>الأدوية المستخدمة لعلاج عدم انتظام ضربات القلب (مثل ديلتيازيم، فيراباميل أو الأميودارون)</li><li>أدوية النترات للذبحة الصدرية (مثل أحادي نترات إيزوسوربيد أو ثلاثي نترات الغليسيريل)</li><li>الأدوية المستخدمة لعلاج قصور القلب (مثل الديجوكسين)</li><li>أي دواء آخر يستخدم لعلاج ارتفاع ضغط الدم (مثل دوكسازوسين، ريزيربين، أملوديبين أو إندورامين)</li><li>الأدوية المستخدمة لعلاج الاكتئاب أو الحالات الصحية العقلية الأخرى (مثل فلوكستين، ومضادات الاكتئاب ثلاثية الحلقات، الباربيتورات، الفينوثيازين، هالوبيريدول أو مثبطات&nbsp; أكسيد مثبطات ماو)</li><li>الأدوية المستخدمة لمنع الجسم رفض الأعضاء بعد عمليات زرع الأعضاء (مثل السيكلوسبورين)</li><li>أدوية خفض نسبة السكر في الدم مثل الأدوية المضادة لمرض السكري عن طريق الفم أو الأنسولين</li><li>الأدوية المستخدمة لخفض ضغط الدم أو لعلاج الصداع النصفي (مثل الكلونيدين أو الإرغوتامين)</li><li>بعض مواد تسكين الألم مثل الأدوية المضادة للالتهابات غير الستيرويدية (المسكنات) (مثل ايبوبروفين أو ديكلوفيناك)</li><li>الأدوية المستخدمة للعلاج بالهرمونات البديلة (مثل هرمون الاستروجين)</li><li>استخدام الكورتيزون لمنع التفاعلات الالتهابية أو التحسسية (مثل بريدنيزولون)</li><li>الأدوية المستخدمة لعلاج الالتهابات البكتيرية (مثل ريفامبيسين أو الاريثروميسين)</li><li>الأدوية المستخدمة لعلاج قرحة المعدة، حرقة وحمض الجزر (مثل السيميتيدين)</li><li>أدوية المستخدمة لعلاج الالتهابات الفطرية (مثل الكيتوكونازول)</li><li>الأدوية المستخدمة في بعض الأحيان في السعال احتقان ونزلات البرد (على سبيل المثال الايفيدرين أو السودوايفيدرين)</li></ul><p>إذا احتجت للتخدير لإجراء عملية جراحية أخبر طبيب المستشفى بأنك تتناول رياكافيلول.</p><p><strong>تناول رياكافيلول مع الطعام والشراب</strong></p><p>يجب أن تتناول رياكافيلول بالماء.</p><p>إذا كنت تتناول رياكافيلول لعلاج قصور القلب، يجب أن تتناول هذا الدواء مع الماء مع وجبات الطعام الخاصة (انظر القسم 3 &#39;كيفية تناول رياكافيلول)</p><p>لا تشرب الكحول في حين تتناول رياكافيلول لأنه قد يفاقم آثار الكحول.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>إذا كنتي حاملا أو مرضعا، لا تتناولي هذا الدواء حتى تتحدثي إلى طبيبك. استشيري الطبيب فورا إذا أصبحت حاملا في حين تتناولين هذا الدواء.</p><p>إسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد تواجهك الدوخة أو التعب أثناء تناول رياكافيلول. هذا أكثر احتمالا لأن يحدث عند أول بدء العلاج، أو عند زيادة الجرعة. إذا حدث هذا، يجب ألا تقود السيارة أو تشغل الآلات. يجب تجنب شرب الكحول، لأنه قد يجعل هذه الأعراض أسوأ. إذا كنت تشعر بالقلق أو تريد المزيد من المعلومات، يجب عليك التحدث مع طبيبك</p><p><strong>معلومات هامة عن بعض مكونات رياكافيلول</strong></p><p>رياكافيلول يحتوي على اللاكتوز (نوع من السكر). إذا كنت قد قيل من قبل الطبيب أن لديك التعصب لبعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائما رياكافيلول تماما كما أخبرك طبيبك. يجب عليك مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدا</p><p>يجب ابتلاع رياكافيلول مع شربة ماء</p><p><strong>ضغط الدم المرتفع</strong></p><p>البالغين: جرعة البداية المعتادة هي 12.5 ملجم مرة واحدة يوميا لمدة اليومين الأولين</p><p>بعد ذلك، يتم زيادة الجرعة إلى 25 ملجم مرة واحدة يوميا. إذا لزم الأمر، فإن طبيبك قد يزيد الجرعة تدريجيا مرة أخرى في فترات من أسبوعين أو أكثر. الحد الأقصى الموصى به الجرعة اليومية هي 50 ملجم (الحد الأقصى للجرعة الواحدة الموصى بها هي 25 ملجم</p><p>كبار السن: طبيبك عادة سوف يبدأ لكم بجرعة 12.5 ملجم مرة واحدة يوميا وتستمر مع هذه الجرعة لمدة العلاج. إذا لزم الأمر، فإن طبيبك قد يزيد الجرعة تدريجيا على فترات من أسبوعين أو أكثر</p><p><strong>الذبحة الصدرية</strong></p><p>البالغين: جرعة البداية المعتادة 12.5 ملجم مرتين في اليوم لمدة اليومين الأولين</p><p>بعد ذلك، يتم زيادة الجرعة إلى 25 ملجم مرتين في اليوم. إذا لزم الأمر، فإن طبيبك قد يزيد الجرعة تدريجيا مرة أخرى في فترات من أسبوعين أو أكثر لجرعة أقصاها 100 ملجم يوميا على جرعتين</p><p>كبار السن: الجرعة المنصوح بها هي 12.5 ملجم مرتين في اليوم لمدة يومي</p><p>بعد ذلك، يمكن زيادة الجرعة إلى 25 ملجم مرتين في اليوم، وهي الجرعة القصوى الموصى بها يوميا</p><p><strong>فشل القلب</strong></p><p>البالغين وكبار السن: لعلاج قصور القلب المستقر، ينبغي أن تؤخذ حبة مرتين في اليوم، في الصباح وفي المساء، ويجب أن تؤخذ مع الطعام من أجل الحد من خطر الآثار الجانبية</p><p>جرعة البداية هي 3.125 ملجم مرتين في اليوم لمدة أسبوعين. سيقوم الطبيب بعد ذلك تدريجيا بزيادة تركيز الأقراص التي تتناولها على فترات من أسبوعين أو أكثر حتى تتلقى الجرعة التي تناسبك</p><p>إذا كنت تزن أقل من 85 كجم، فالحد الأقصى للجرعة الموصى بها من رياكافيلول هي 25 ملجم مرتين في اليوم، إذا كنت تزن أكثر من 85 كجم، طبيبك قد يزيد الجرعة إلى 50 ملجم مرتين في اليوم</p><p>لعلاج فشل القلب، فمن المستحسن أن العلاج برياكافيلول يبدأ ويرصد بعناية من قبل اختصاصي المستشفى</p><p>إذا توقفت عن تناول رياكافيلول لأكثر من أسبوعين ستحتاج إلى العودة إلى جرعة البداية وزيادة الجرعة تدريجيا مرة أخرى</p><p>في بعض الأحيان، فشل القلب قد يزداد سوءا مع الأخذ رياكافيلول، وخاصة في بداية العلاج. هذا قد يؤدي إلى زيادة الأعراض (مثل التعب وضيق في التنفس) وعلامات احتباس السوائل مثل زيادة الوزن وتورم في الساقين</p><p>إذا ساءت الأعراض أو الحالة أثناء أخذ رياكافيلول، فعليك أن تخبر طبيبك، كما انه أو انها قد تحتاج إلى تغيير جرعة من الأدوية الأخرى أو من رياكافيلول وقتما تتناول رياكافيلول، تأكد من أن تستمر مع العلاجات الأخرى الخاصة بك لقصور القلب بناء على مشورة الطبيب</p><p><strong>المرضى الذين يعانون من مشاكل في الكبد</strong></p><p>اعتمادا على حالتك، طبيبك قد يقلل من الجرعة مقارنة مع تلك الموصى بها أعلاه</p><p><strong>الأطفال والمراهقين (تحت 18 سنة)</strong></p><p>لا ينصح رياكافيلول في هذه الفئة العمرية</p><p><strong>إذا تناولت رياكافيلول أكثر مما يجب</strong></p><p>إذا قمت بطريق الخطأ بتناول الكثير من الأقراص، اتصل بطبيبك على الفور أو اذهب إلى أقرب قسم للطوارئ بالمستشفى. قد تشعر بالدوار والاعياء، الاغماء، بضيق التنفس / وأزيز، نعاس شديد، أو تحدث لك التشنجات</p><p><strong>إذا نسيت أن تتناول رياكافيلول</strong></p><p>إذا كنت قد نسيت أن تتناول جرعة، لا تقلق. خذ أخرى في أقرب وقت عندما تتذكر، شريطة انه ليس الوقت لتناول جرعة تالية تقريبا. تناول القرص القادم في الوقت العادي، ولكن لا تأخذ جرعة مضاعفة لتعويض الحبة المنسية</p><p><strong>إذا توقفت عن تناول رياكافيلول</strong></p><p>لا تتوقف فجأة عن تناول رياكافيلول قبل أن تتحدث إلى طبيبك حول هذا الموضوع. قد يكون لذلك آثار جانبية إذا أوقفت الأقراص فجأة. طبيبك سيخبرك عن كيفية تقليل الجرعة تدريجيا ثم إيقاف هذا الدواء. إذا كنت تتناول أيضا دواء يسمى الكلونيدين، لا تتوقف أبدا العلاج إلا إذا طلب منه الطبيب ذلك</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، وعلى الرغم من أن ليس الجميع يحصل عليها</p><p>يتم عرض تواتر من الاثار الجانبية المحتملة في الجدول أدناه:</p><p><strong>شائعة جدا</strong>: تحدث في أكثر من 1 من كل 10 مستخدمين</p><p><strong>شائعة</strong>: تحدث في أقل من 1 من كل 10 مستخدمين، ولكن أكثر من 1 من كل 100 مستخدم</p><p><strong>غير شائعة</strong>: تحدث في أقل من 1 من كل 100 مستخدم ولكن أكثر من 1 من كل 1،000 مستخدم</p><p><strong>نادرة</strong>: تحدث في أقل من 1 من كل 1،000 مستخدم، ولكن أكثر من 1 من كل 10،000 مستخدم</p><p><strong>نادرة جدا</strong>: تحدث في أقل من 1 من كل 10،000 مستخدم، بما في ذلك حالات معزولة</p><p>غالبية الآثار الجانبية مرتبطة بالجرعة وتختفي عندما يتم تقليل الجرعة أو وقف علاج. يمكن أن تحدث بعض الآثار الجانبية في بداية العلاج وتزول عفويا مع استمرار العلاج</p><p><strong>شائعة جدا:</strong></p><ul><li>دوخة</li><li>صداع</li><li>تعب</li><li>هبوط بضغط الدم</li><li>قصور بالقلب</li></ul><p><strong>شائعة:</strong></p><ul><li>التهاب الشعب الهوائية والالتهاب الرئوي وعدوى الجهاز التنفسي العلوي</li><li>التهابات المسالك البولية</li><li>انخفاض أعداد خلايا الدم الحمراء</li><li>زيادة في الوزن</li><li>ارتفاع مستويات الكولسترول</li><li>فقدان السيطرة على نسبة السكر في الدم في مرضى السكري</li><li>الاكتئاب والمزاج المكتئب</li><li>اضطراب البصرية</li><li>انخفاض الدمع، تهيج العين</li><li>معدل ضربات القلب البطيء</li><li>الأوديما (تورم الجسم أو أجزاء من الجسم)، والحمل الزائد من السوائل، وزيادة حجم الدم في الجسم</li><li>الدوخة عند الوقوف بسرعة</li><li>مشاكل الدورة الدموية (تشمل علامات برودة اليدين والقدمين)، تيبس الشرايين (تصلب الشرايين) تفاقم الأعراض لدى المرضى الذين يعانون من مرض رينود (أصابع اليدين أو القدمين تتحول لمزرقة أولا، ثم بيضاء، ثم محمرة مع الألم) أو العرج (ألم في الساقين الذي يزداد سوءا عند المشي)</li><li>مشاكل الربو والتنفس</li><li>تراكم السوائل في الرئتين</li><li>الإسهال</li><li>الشعور بالضيق، والقيء، وآلام المعدة، وعسر الهضم</li><li>آلام (على سبيل المثال في الذراعين والساقين)</li><li>القصور الكلوي الحاد واضطرابات في وظائف الكلى في المرضى الذين يعانون من تيبس الشرايين و / أو اختلال وظائف الكلى</li><li>صعوبة في التبول</li><li>ارتفاع مستوى البوتاسيوم في الدم</li></ul><p><strong>غير شائعة:</strong></p><ul><li>اضطراب النوم</li><li>الارتباك</li><li>الإغماء</li><li>إحساس غير طبيعي</li><li>اضطرابات في نظام التوصيل في القلب، والذبحة الصدرية (بما في ذلك ألم في الصدر)</li><li>بعض ردود الفعل الجلد (آفات جلدية مثل حساسية الجلد، وخلايا النحل، والحكة والتهاب الجلد، وزيادة التعرق، والصدفية أو الحزاز المسطح)</li><li>تساقط الشعر</li><li>العجز الجنسي</li></ul><p><strong>نادرة:</strong></p><ul><li>انخفاض عدد صفائح الدم (الصفيحات)</li><li>جفاف الفم</li><li>انسداد الأنف</li></ul><p><strong>نادر جدا:</strong></p><ul><li>انخفاض أعداد خلايا الدم البيضاء</li><li>الحساسية</li><li>التغييرات في اختبار وظائف الكبد</li><li>تسرب البول اللاإرادي لدى النساء (سلس البول)</li></ul><p>إذا حصلت على أي آثار جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي آثار جانبية غير المذكورة في هذه النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>-&nbsp;</strong>يحفظ بعيدا عن متناول أيدي ونظر الاطفال-&nbsp;</p><p>- يحفظ في درجة حرارة أقل من 30 درجة مئوية-&nbsp;</p><p>- يحفظ في العبوة الأصلية للحماية من الضوء والرطوبة-&nbsp;</p><p><strong>-&nbsp;</strong>لا تستخدم رياكافيلول أقراص بعد تاريخ انتهاء الصلاحية المدون على الشريط والعلبة، التاريخ يرجع إلى آخر يوم في هذا الشهر-&nbsp;</p><p><strong>-&nbsp;</strong>يجب ألا يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل قرص مغلف يحتوي على كارفيديلول (دستور الأدوية البريطاني) 25 ملجم</p><p>المكونات الأخرى: غيرها من المكونات: اللاكتوز درجة دي سي، ميكروكريستالين السيلولوز &nbsp;بي اتش 102، كروسبوفيدون، كولويدال السيليكا اللامائي، ستيرات المغنيسيوم</p><p>مادة مغلفة: أوبادري الأصفر 31</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>رياكافيلول 25 ملجم: أقراص مغلفة لونها أصفر، مستديرة، عليها (MC 12) على أحد الاوجه وخط للتقسيم على الوجه الآخر.</p><p>العبوة:</p><p>كل عبوة من رياكافيلول 25 ملجم تحتوي على 30 قرص مغلف: عبارة عن 3 أشرطة (Alu)/Alu)، كل شريط يحتوي على 10 أقراص مغلفة.</p><p>عبوات مستشفيات تحتوي على أقراص من رياكافيلول 25 ملجم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع</strong></p><p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Riacavilol 25 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet contains 25 mg of carvedilol.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. 
   
Yellow coloured film coated circular tablets having “MC 12” on one side and a break line on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Essential hypertension</p><p>Chronic stable angina pectoris</p><p>Adjunctive treatment of moderate to severe stable chronic heart failure</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral use.</p><p><strong>Essential Hypertension</strong></p><p>Riacavilol may be used for the treatment of hypertension alone or in combination with other antihypertensives, especially thiazide diuretics. Once daily dosing is recommended, however the recommended maximum single dose is 25 mg and the recommended maximum daily dose is 50 mg.</p><p><em>Adults:</em></p><p>The recommended initial dose is 12.5 mg once a day for the first two days. Thereafter, the treatment is continued at the dose 25 mg/day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely.</p><p><em>Elderly:</em></p><p>The recommended initial dose in hypertension is 12.5 mg once a day which may also be sufficient for continued treatment.</p><p>However, if the therapeutic response is inadequate at this dose, the dose may be further increased gradually at intervals of two weeks or more rarely.</p><p><strong>Chronic stable angina pectoris:</strong></p><p>A twice-daily regimen is recommended.</p><p><em>Adults</em></p><p>The recommended initial dosage is 12.5 mg twice a day for the first two days. Thereafter, the treatment is continued at the dose 25 mg twice a day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely to the recommended maximum dose of 100 mg a day divided into two doses (twice daily).</p><p><em>Elderly</em></p><p>The recommended initial dose is 12.5 mg twice daily for two days. Thereafter, the treatment is continued at the dose 25 mg twice daily, which is the recommended maximum daily dose.</p><p><strong>Heart Failure:</strong></p><p>Riacavilol is given in moderate to severe heart failure in addition to conventional basic therapy with diuretics, ACE inhibitors, digitalis, and/or vasodilators. The patient should be clinically stable (no change in NYHA-class, no hospitalisation due to heart failure) and the basic therapy must be stabilized for at least 4 weeks prior to treatment. Additionally the patient should have a reduced left ventricular ejection fraction and heart rate should be &gt; 50 bpm and systolic blood pressure &gt; 85 mm Hg (see section 4.3).</p><p>The initial dose is 3.125 mg twice a day for two weeks. If this dose is tolerated, the dose may be increased slowly with intervals of not less than two weeks up to 6.25 mg twice a day, then up to 12.5 mg twice a day and finally up to 25 mg twice a day. The dosage should be increased to the highest tolerable level.</p><p>The recommended maximum dosage is 25 mg twice a day for patients with a body weight of less than 85 kg, and 50 mg twice a day for patients with a body weight above 85 kg, provided that the heart failure is not severe.&nbsp;<u>A dose increase to 50 mg twice daily should be performed carefully under close medical supervision of the patient.</u></p><p>Transient worsening of symptoms of heart failure may occur at the beginning of treatment or due to a dose increase, especially in patients with severe heart failure and/or under high dose diuretic treatment. This does usually not call for discontinuation of treatment, but dose should not be increased. The patient should be monitored by a physician/cardiologist for two hours after starting treatment or increasing the dose. Before each dose increase, an examination should be performed for potential symptoms of worsening heart failure or for symptoms of excessive vasodilatation (e.g. renal function, body weight, blood pressure, heart rate and rhythm). Worsening of heart failure or fluid retention is treated by increasing the dose of diuretic, and the dose of carvedilol should not be increased until the patient is stabilized. If bradycardia appears or in case of lengthening of AV conduction, the level of digoxin should first be monitored. Occasionally it may be necessary to reduce the carvedilol dose or temporarily discontinue treatment altogether. Even in these cases, carvedilol dose titration can often be successfully continued.</p><p>Renal function, thrombocytes and glucose (in case of NIDDM and/or IDDM) should be monitored regularly during dose titration. However, after dose titration the frequency of monitoring can be reduced.</p><p>If carvedilol has been withdrawn for more than two weeks, the therapy should be reinitiated with 3.125 mg twice a day and increased gradually according to the above recommendations.</p><p><em>Renal insufficiency</em></p><p>Dosage must be determined for each patient individually, but according to pharmacokinetic parameters there is no evidence that dose adjustment of carvedilol in patients with renal impairment is necessary.</p><p><em>Moderate hepatic dysfunction</em></p><p>Dose adjustment may be required.</p><p><em>Paediatric population (&lt; 18 years)</em></p><p>Riacavilol is not recommended for the use in children below 18 years of age due to insufficient data on the efficacy and safety of Riacavilol.</p><p><em>Elderly</em></p><p>Elderly patients may be more susceptible to the effects of Riacavilol and should be monitored more carefully.</p><p>As with other beta-blockers and especially in patients with coronary disease, the withdrawal of carvedilol should be done gradually (see section 4.4).</p><p><em>Methods of administration</em></p><p>The tablets should be taken with the adequate supply of fluid. It is recommended that heart failure patients take their carvedilol medication with food to allow the absorption to be slower and the risk of orthostatic hypotension to be reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the carvedilol or to any of the excipients of Riacavilol listed in section 6.1.
• Heart failure belonging to NYHA Class IV of the heart failure classification with marked fluid retention or overload requiring intravenous inotropic treatment.
• Chronic obstructive pulmonary disease with bronchial obstruction (see section 4.4).
• Clinically significant hepatic dysfunction.
• Bronchial asthma.
• AV block, degree II or III (unless a permanent pacemaker is in place).
• Severe bradycardia (<50 bpm).
• Sick sinus syndrome (incl. sino-atrial block).
• Cardiogenic shock.
• Severe hypotension (systolic blood pressure below 85 mmHg).
• Prinzmetal's angina.
• Untreated phaeochromocytoma.
• Metabolic acidosis.
• Severe peripheral arterial circulatory disturbances.
Concomitant intravenous treatment with verapamil or diltiazem (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warnings to be considered particularly in heart failure patients</p><p>In chronic heart failure patients carvedilol should be administered principally in addition to diuretics, ACE inhibitors, digitalis and/or vasodilators. Initiation of therapy should be under the supervision of a hospital physician. Therapy should only be initiated, if the patient is stabilized on conventional basic therapy for at least 4 weeks. Patients with severe heart failure, salt and volume depletion, elderly or patients with low basic blood pressure should be monitored for approximately 2 hours after the first dose or after dose increase as hypotension may occur. Hypotension due to excessive vasodilatation is initially treated by reducing the dose of the diuretic. If symptoms still persist, the dose of any ACE inhibitor may be reduced. At the start of therapy or during up-titration of Riacavilol worsening of heart failure or fluid retention may occur. In these cases, the dose of diuretic should be increased. However, sometimes it will be necessary to reduce or withdraw Riacavilol medication. The carvedilol dose should not be increased before symptoms due to the worsening of heart failure or hypotension due to vasodilatation are under control.</p><p>Reversible deterioration of renal function has been observed during carvedilol therapy in heart failure patients with low blood pressure (systolic &lt; 100 mm Hg), ischaemic heart disease and generalized atherosclerosis, and/or underlying renal insufficiency. In heart failure patients with these risk factors, renal function should be monitored during dose titration of carvedilol. If significant worsening of renal function occurs, the carvedilol dose must be reduced or therapy must be discontinued.</p><p>In patients with chronic heart failure treated with digitalis, carvedilol should be given with caution, as digitalis and carvedilol both lengthen the AV conduction time (see section 4.5).</p><p>Other warnings as regards carvedilol and beta-blockers in general</p><p>Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal&#39;s variant angina. There is no clinical experience with carvedilol in these patients, although the alpha-blocking activity of carvedilol may prevent such symptoms. However, caution should be taken in the administration of carvedilol to patients suspected of having Prinzmetal&#39;s variant angina.</p><p>Patients with a chronic obstructive pulmonary disease with a tendency towards bronchospasms who are not treated with oral or inhalation medicine should only be given carvedilol if the expected improvement outweighs the possible risk. Patients should be monitored closely in the initial phase, and titration of carvedilol and carvedilol dose should be reduced in case of bronchospasms.</p><p>Carvedilol may mask symptoms and signs of acute hypoglycaemia. Impaired blood glucose control may occasionally occur in patients with diabetes mellitus and heart failure in connection with the use of carvedilol. Therefore, close monitoring of diabetic patients receiving carvedilol is required by means of regular blood glucose measurements, especially during dose titration, and adjustment of antidiabetic medication as necessary (see section 4.5). Blood glucose levels should also be closely monitored after a longer period of fasting.</p><p>Riacavilol may mask features (symptoms and signs) of thyrotoxicosis.</p><p>Riacavilol may cause bradycardia. If there is a decrease in pulse rate to less than 55 beats per minute, and symptoms associated with bradycardia occur, the carvedilol dose should be reduced.</p><p>When carvedilol is used concomitantly with calcium channel blocking agents such as verapamil and diltiazem or with other antiarrhythmics, specifically amiodarone, the patient&#39;s blood pressure and ECG have to be monitored. Intravenous co-administration should be avoided (see section 4.5).</p><p>Cimetidine should be administered only with caution concomitantly as effects of carvedilol may be increased (see section 4.5).</p><p>Persons wearing contact lenses should be advised of a possible reduction of the secretion of lacrimal fluid.</p><p>Care should be taken in administrating carvedilol to patients with a history of serious hypersensitivity reactions and in those undergoing desensitisation therapy as beta-blockers may increase both the sensitivity towards allergens and the seriousness of anaphylactic reactions. Cautions should be exercised when prescribing beta-blockers to patients with psoriasis since skin reactions may be aggravated.</p><p>Riacavilol should be used with caution in patients with peripheral vascular diseases, as beta-blockers may aggravate symptoms of the disease. The same also applies to those with Raynaud&#39;s syndrome, as there may be exacerbation or aggravation of symptoms.</p><p>Patients who are known as poor metabolizers of debrisoquine, should be closely monitored during initiation of therapy (see section 5.2).</p><p>Since there is limited clinical experience, carvedilol should not be administered in patients with labile or secondary hypertension, orthostasis, acute inflammatory heart disease, haemodynamic relevant obstruction of heart valves or outflow tract, end-stage peripheral arterial disease, concomitant treatment with &alpha;1-receptor antagonist or &alpha;2-receptor agonist.</p><p>&nbsp;</p><p>In patients with phaeochromocytoma, an initial treatment with alpha-blockers should be started before using any beta-blocker. Although carvedilol exercises alpha and beta blockade there is not sufficient experience in this disease, therefore caution should be advised in these patients.</p><p>Because of its negative dromotropic action, carvedilol should be given with caution to patients with first degree heart block.</p><p>Beta-blockers reduce the risk of arrhythmias at anasthesia, however the risk of hypotension may be increased as well. Caution should therefore be observed with the use of certain anaesthetic medicines. Newer studies suggest however, a benefit of beta-blockers in preventing perioperative cardiac morbidity and reduction of the incidence of cardiovascular complications.</p><p>As with other beta-blockers, carvedilol should not be discontinued abruptly. This applies in particular to patients with ischaemic heart disease. Riacavilol therapy must be discontinued gradually within two weeks, e.g. by reducing the daily dose to half every three days. If necessary, at the same time replacement therapy should be initiated to prevent exacerbation of angina pectoris.</p><p>Riacavilol contains lactose monohydrate and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Antiarrhythmics.</em></strong></p><p>Isolated cases of conduction disturbance (rarely compromised haemodynamics) have been reported, if oral carvedilol and oral diltiazem verapamil and/or amiodarone are given concomitantly. As with other beta-blockers, ECG and blood pressure should be monitored closely when concomitantly administering calcium-channel-blockers of the verapamil and diltiazem type due to the risk of AV conduction disorder or risk of cardiac failure (synergetic effect). Close monitoring should be done in case of co-administration of carvedilol, and amiodarone therapy (oral) or class I antiarrhythmics. Bradycardia, cardiac arrest, and ventricular fibrillation have been reported shortly after initiation of beta-blocker treatment in patients receiving amiodarone. There is a risk of cardiac failure in case of class Ia or Ic antiarrhythmics concomitant intravenous therapy.</p><p>Concomitant treatment with reserpine, guanethidine, methyldopa, guanfacine and monoamine oxidase inhibitors (exception MAO-B inhibitors) can lead to additional decrease in heart rate. And hypotension Monitoring of vital signs is recommended.</p><p><strong><em>Dihydropyridines.</em></strong></p><p>The administration of dihydropyridines and carvedilol should be done under close supervision as heart failure and severe hypotension have been reported.</p><p><strong><em>Nitrates.</em></strong></p><p>Increased hypotensive effects.</p><p><strong><em>Cardiac glycosides.</em></strong></p><p>An increase of steady state digoxin levels by approximately 16% and of digitoxin by approximately 13% has been seen in hypertensive patients in connection with the concomitant use of carvedilol and digoxin. Monitoring of plasma digoxin concentrations is recommended when initiating, discontinuing or adjusting treatment with carvedilol.</p><p><strong><em>Other antihypertensive medicines.</em></strong></p><p>Riacavilol may potentiate the effects of other concomitantly administered antihypertensives (e.g. &alpha;1-receptor antagonists) and medicines with antihypertensive adverse reactions such as barbiturates, phenothiazines, tricyclic antidepressants, vasodilating agents and alcohol.</p><p><strong><em>Cyclosporin.</em></strong></p><p>Modest increases in mean trough cyclosporine concentrations were observed following the initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection. In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations with the therapeutic range, while in the remainder no adjustment was needed. On average, the dose of cyclosporine was reduced about 20% in these patients. Due to wide interindividual variability in the dose adjustments required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.</p><p><strong><em>Antidiabetics including insulin.</em></strong></p><p>The blood sugar-lowering effect of insulin and oral diabetic medicines may be intensified. Symptoms of hypoglycaemia may be masked. In diabetic patients regular monitoring of blood glucose levels is necessary.</p><p><strong><em>Clonidine.</em></strong></p><p>In case of withdrawal of both carvedilol and clonidine, carvedilol should be withdrawn several days before the stepwise withdrawal of clonidine.</p><p><strong><em>Inhalational anaesthetics.</em></strong></p><p>Caution is advised in case of anaesthesia due to synergistic, negative inotrope and hypotensive effect of carvedilol and certain anaesthetics.</p><p><strong><em>NSAIDs, estrogens and corticosteroids.</em></strong></p><p>The antihypertensive effect of carvedilol is decreased due to water and sodium retention.</p><p><strong><em>Medicines inducing or inhibiting cytochrome P450 enzymes.</em></strong></p><p>Patients receiving medicines that induce (e.g. rifampicin and barbiturates) or inhibit (e.g. cimetidine, ketoconazole, fluoxetine, haloperidol, verapamil, erythromycine) cytochrome P450 enzymes have to be monitored closely during concomitant treatment with carvedilol as serum carvedilol concentrations may be reduced by the first agents and increased by the enzyme inhibitors.</p><p>Rifampicin reduced plasma concentrations of carvedilol by about 70%. Cimetidine increased AUC by about 30% but caused no change in Cmax. Care may be required in those patients receiving inducers of mixed function oxidases e.g. rifampicin, as serum levels of carvedilol may be reduced, or inhibitors of mixed function oxidases e.g. cimetidine, as serum levels may be increased. However, based on the relatively small effect of cimetidine on carvedilol drug levels, the likelihood of any clinically important interaction is minimal.</p><p><strong><em>Sympathomimetics with alpha-mimetic and beta-mimetic effects.</em></strong></p><p>Risk of hypertension and excessive bradycardia.</p><p><strong><em>Ergotamine.</em></strong></p><p>Vasoconstriction increased.</p><p><strong><em>Neuromuscular blocking agents.</em></strong></p><p>Increased neuromuscular block.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>There are no adequate data from the use of carvedilol in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Beta-blockers reduce placental perfusion which may result in intrauterine fetal death and immature and premature deliveries. In addition, adverse reactions (especially hypoglycaemia, hypotension, bradycardia, respiratory depression and hypothermia) may occur in the fetus and neonate. There is an increased risk of cardiac and pulmonary complications in the neonate in the postnatal period. Riacavilol should not be used during pregnancy unless clearly necessary (that is if the potential benefit for the mother outweighs the potential risk for the fetus/neonate). The treatment should be stopped 2-3 days before expected birth. If this is not possible the new-born has to be monitored for the first 2-3 days of life.</p><p><strong><u>Breastfeeding</u></strong></p><p>Riacavilol is lipophilic and according to results from studies with lactating animals, carvedilol and its metabolites are excreted in breast milk and, therefore, mothers receiving carvedilol should not breast-feed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product has minor influence on the ability to drive and use machines. Some individuals may have reduced alertness especially on initiation and adjustment of medication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>(a) Summary of the safety profile</em></p><p>The frequency of adverse reactions is not dose-dependent, with the exception of dizziness, abnormal vision and bradycardia.</p><p><em>(b) Tabulated list of adverse reactions</em></p><p>The risk of most adverse reactions associated with carvedilol is similar across all indications.</p><p>Exceptions are described in subsection (c).</p><p>Frequency categories are as follows:</p><p>Very common &ge; 1/10</p><p>Common &ge; 1/100 and &lt; 1/10</p><p>Uncommon &ge; 1/1,000 and &lt; 1/100</p><p>Rare &ge; 1/10,000 and &lt; 1/1,000</p><p>Very rare &lt; 1/10,000</p><p><em>Infections and infestations</em></p><p>Common: Bronchitis, pneumonia, upper respiratory tract infection, urinary tract infection</p><p><em>Blood and lymphatic system disorders</em></p><p>Common: Anaemia</p><p>Rare: Thrombocytopaenia</p><p>Very rare: Leukopenia</p><p><em>Immune system disorders</em></p><p>Very rare: Hypersensitivity (allergic reaction)</p><p><em>Metabolism and nutrition disorders</em></p><p>Common: Weight increase, hypercholesterolaemia, impaired blood glucose control (hyperglycaemia, hypoglycaemia) in patients with pre-existing diabetes and Hyperkalaemia.</p><p><em>Psychiatric disorders</em></p><p>Common: Depression, depressed mood</p><p>Uncommon: Sleep disorders, confusion</p><p><em>Nervous system disorders</em></p><p>Very common: Dizziness, headache</p><p>Uncommon: Presyncope, syncope, paraesthesia</p><p><em>Eye disorders</em></p><p>Common: Visual impairment, lacrimation decreased (dry eye), eye irritation</p><p><em>Cardiac disorders</em></p><p>Very common: Cardiac failure</p><p>Common: Bradycardia, oedema, hypervolaemia, fluid overload</p><p>Uncommon: Atrioventricular block, angina pectoris</p><p><em>Vascular disorders</em></p><p>Very common: Hypotension</p><p>Common: Orthostatic hypotension, disturbances of peripheral circulation (cold extremities, peripheral vascular disease, exacerbation of intermittent claudication and Reynaud&#39;s phenomenon)</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Common: Dyspnoea, pulmonary oedema, asthma in predisposed patients</p><p>Rare: Nasal congestion</p><p><em>Gastrointestinal disorders</em></p><p>Common: Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain</p><p>Rare: dry mouth</p><p><em>Hepatobiliary disorders</em></p><p>Very rare: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gammaglutamyltransferase (GGT) increased</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Uncommon: Skin reactions (e.g. allergic exanthema, dermatitis, urticaria, pruritus, psoriatic and lichen planus like skin lesions and increased sweating), alopecia</p><p>Very rare: Severe cutaneous adverse reactions (e.g. Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis)</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Common: Pain in extremities</p><p><em>Renal and urinary disorders</em></p><p>Common: Renal failure and renal function abnormalities in patients with diffuse vascular disease and/or underlying renal insufficiency, micturition disorders</p><p>Very rare: Urinary incontinence in women</p><p><em>Reproductive system and breast disorders</em></p><p>Uncommon: Erectile dysfunction</p><p><em>General disorders and administration site conditions</em></p><p>Very common: Asthenia (fatigue)</p><p>Common: Pain</p><p><em>(c) Description</em>&nbsp;of&nbsp;<em>selected adverse</em>&nbsp;<em>reactions</em></p><p>Dizziness, syncope, headache and asthenia are usually mild and are more likely to occur at the beginning of treatment.</p><p><em>In patients with congestive heart failure, worsening cardiac failure and fluid retention may occur during up-titration of carvedilol dose (see section 4.4).</em></p><p>Cardiac failure is a commonly reported adverse event in both placebo and carvedilol-treated patients (14.5% and 15.4% respectively, in patients with left ventricular dysfunction following acute myocardial infarction).</p><p>Reversible deterioration of renal function has been observed with carvedilol therapy in chronic heart failure patients with low blood pressure, ischaemic heart disease and diffuse vascular disease and/or underlying renal insufficiency (see section 4.4).</p><p><em>As a class, beta-adrenergic receptor blockers may cause latent diabetes to become manifest, manifest diabetes to be aggravated, and blood glucose counter-regulation to be inhibited.</em></p><p>Riacavilol may cause urinary incontinence in women which resolves upon discontinuation of the medication.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effects:</strong></p><p><strong>National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>To call the executive management of vigilance and crisis management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 2340</li><li>Toll-free: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and signs</strong></p><p>In the event of overdose, there may be severe hypotension, bradycardia, heart failure, cardiogenic shock and cardiac arrest. There may also be respiratory problems, bronchospasm, vomiting, disturbed consciousness and generalized seizures.</p><p><strong>Treatment</strong></p><p>In addition to general supportive treatment, the vital parameters must be monitored and corrected, if necessary, under intensive care conditions.</p><p>Atropine can be used for excessive bradycardia, while to support ventricular function intravenous glucagon, or sympathomimetics (dobutamine, isoprenaline) are recommended. If positive inotropic effect is required, phosphodiesterase inhibitors (PDE) should be considered. If peripheral vasodilation dominates the intoxication profile then norfenephrine or noradrenaline should be administered with continuous monitoring of the circulation. In the case of drug-resistant bradycardia, pacemaker therapy should be initiated.</p><p>For bronchospasm, &beta;-sympathomimetics (as aerosol or intravenous) should be given, or aminophylline may be administered intravenously by slow injection or infusion. In the event of seizures, slow intravenous injection of diazepam or clonazepam is recommended.</p><p>Carvedilol is highly protein-bound. Therefore, it cannot be eliminated by dialysis.</p><p>In cases of severe overdose with symptoms of shock, supportive treatment must be continued for a sufficiently long period, i.e. until the patient&#39;s condition has stabilised, as a prolongation of elimination half-life and redistribution of carvedilol from deeper compartments are to be expected.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Alpha and beta blocking agents..</p><p><strong>ATC code:</strong> C07AG02</p><p>Carvedilol is a vasodilatory non-selective beta-blocker, which reduces the peripheral vascular resistance by selective alpha 1- receptor blockade and suppresses the renin-angiotensin system through non-selective beta-blockade. Plasma renin activity is reduced and fluid retention is rare.</p><p>Carvedilol has no intrinsic sympathomimetic activity (ISA). Like propranolol, it has membrane stabilising properties.</p><p>Carvedilol is a racemate of two stereoisomers. Both enantiomers were found to have alpha-adrenergic blocking activity in animal models. Non-selective beta<sub>1</sub>- and beta<sub>2</sub>- adrenoceptor blockade is attributed mainly to the S(-) enantiomer.</p><p>The antioxidant properties of carvedilol and its metabolites have been demonstrated in&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;animal studies and&nbsp;<em>in vitro</em>&nbsp;in a number of human cell types.</p><p>In hypertensive patients, a reduction in blood pressure is not associated with a concomitant increase in peripheral resistance, as observed with pure beta-blocking agents. Heart rate is slightly decreased. Stroke volume remains unchanged. Renal blood flow and renal function remain normal, as does peripheral blood flow, therefore, cold extremities, often observed with beta-blockers, are rarely seen. In hypertensive patients carvedilol increases the plasma norepinephrine concentration.</p><p>In prolonged treatment of patients with angina, carvedilol has been seen to have an anti-ischaemic effect and to alleviate pain. Haemodynamic studies demonstrated that carvedilol reduces ventricular pre- and after-load. In patients with left ventricular dysfunction or congestive heart failure, carvedilol has a favourable effect on haemodynamics and left ventricular ejection fraction and dimensions.</p><p>Carvedilol has no negative effect on the serum lipid profile or electrolytes. The ratio of HDL (high-density lipoproteins) and LDL (low-density lipoproteins) remains normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Carvedilol is rapidly absorbed after oral administration. In healthy subjects, maximum serum concentration is achieved approximately 1 hour after administration. The absolute bioavailability of carvedilol in humans is approximately 25%.</p><p>There is a linear relationship between dose and serum concentrations of carvedilol. Food intake did not affect the bioavailability or the maximum serum concentration, although the time needed to reach maximum serum concentration is prolonged.</p><p><strong>Distribution</strong></p><p>Carvedilol is highly lipophilic. The plasma protein binding is about 98 to 99%. The volume of distribution is approximately 2 l / kg and increases in patients with liver cirrhosis.</p><p><strong>Biotransformation</strong></p><p>In humans and in animal species studied, carvedilol is extensively metabolized to several metabolites which are excreted primarily in bile. The first pass effect after oral administration is about 60-75%. The enterohepatic circulation of the parent substance was demonstrated in animals.</p><p>Carvedilol is extensively metabolized in the liver, glucuronidation being one of the main reactions. The demethylation and hydroxylation at the phenol ring produce 3 active metabolites with blocking activity of beta-adrenergic receptors.</p><p>According to preclinical studies, the beta-blocking activity of the metabolite 4 - hydroxyphenol is approximately 13 times higher than that of carvedilol. The three active metabolites have a weak vasodilating activity, compared with carvedilol. In humans, their concentrations are about 10 times lower than the parent substance. Two of the carbazole-hydroxy metabolites are extremely potent antioxidants, showing a potency 30-80 times that of carvedilol.</p><p><strong>Elimination</strong></p><p>The average half-life of elimination of carvedilol is approximately 6 hours. The plasma clearance is approximately 500-700 ml / min. Elimination is mainly via the bile, and excretion mainly via the faeces. A minor part is eliminated renally in the form of various metabolites.</p><p>Pharmacokinetics in Special Populations</p><p><strong><u>Patients with renal impairment</u></strong></p><p>In some of the hypertensive patients with moderate to severe renal impairment (creatinine clearance &lt; 30 ml/min), an increase in plasma carvedilol concentrations of approximately 40-50 % was seen compared to patients with normal renal function. Peak plasma concentrations in patients with renal insufficiency increased also by an average of 10-20 %. However, there was a large variation in the results. Since carvedilol is primarily excreted via the faeces, significant accumulation in patients with renal impairment is unlikely.</p><p>In patients with moderate to severe renal impairment there is no need to modify carvedilol dosage (see section 4.2).</p><p><strong><u>Patients with liver failure</u></strong></p><p>In patients with liver cirrhosis, the systemic availability of carvedilol is increased 80% due to reduced first pass effect. Therefore, carvedilol is contraindicated in patients with clinically manifest hepatic impairment (see section 4.3 Contraindications).</p><p><strong><u>Use in elderly</u></strong></p><p>Age had a statistically significant effect on pharmacokinetic parameters of carvedilol in hypertensive patients. A study in elderly hypertensive patients showed no difference between the adverse event profile of this group and younger patients. Another study involving elderly patients with coronary artery disease showed no difference in reported adverse reactions vs. those that were reported by younger patients.</p><p><strong><u>Use in pediatrics</u></strong></p><p>The available information on pharmacokinetics in subjects younger than 18 years is limited.</p><p><strong><u>Diabetic patients</u></strong></p><p>In hypertensive patients with type 2 diabetes was not observed effect of carvedilol on blood glucose (fasting or postprandial) and glycosylated haemoglobin A1, it was not necessary to change the dose of antidiabetic drugs.</p><p>In patients with type 2 diabetes, carvedilol had no statistically significant influence on the glucose tolerance test. In nondiabetic hypertensive patients with altered insulin sensitivity (Syndrome X), carvedilol increased insulin sensitivity. The same results were observed in hypertensive patients with type 2 diabetes.</p><p><strong><u>Heart failure</u></strong></p><p>In a study in 24 patients with heart failure, the clearance of R-and S-carvedilol was significantly lower than previously estimated in healthy volunteers. These results suggested that the pharmacokinetics of R-and S-carvedilol is significantly altered by heart failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carvedilol demonstrated no mutagenic or carcinogenic potential.</p><p>High doses of carvedilol impaired fertility and affected pregnancy in rats (increased resorptions). Decreased fetal weight and delayed skeletal development were also seen in rats. Embryotoxicity (increased post-implantation loss) occurred in rats and rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Tablet core</em></strong></p><p>Lactose (DC grade)</p><p>Microcrystalline cellulose PH102</p><p>Crospovidone</p><p>Colloidal anhydrous silica</p><p>Magnesium stearate</p><p><strong><em>Tablet coating</em></strong></p><p>Riacavilol 25 mg: Opadry yellow 31K52613</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg; C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>RIACAVILOL 25 MG TABLET&nbsp;&nbsp; </strong></p><p>Blister Pack of Aluminium / Aluminium foil containing 10 film coated tablets.&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O. Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorization holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4/2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>